tiprankstipranks
Advertisement
Advertisement

MLTX Stock Latest News

MoonLake Immunotherapeutics Announces $200 Million Public Offering
Company AnnouncementsMoonLake Immunotherapeutics Announces $200 Million Public Offering
16d ago
8K
MLTX
MoonLake Immunotherapeutics 9M share Secondary priced at $20.00
PremiumThe Fly
MoonLake Immunotherapeutics 9M share Secondary priced at $20.00
17d ago
MLTX
Buy Rating Reaffirmed on Sonelokimab’s Strong HS Data and Regulatory De-Risking; $30 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on Sonelokimab’s Strong HS Data and Regulatory De-Risking; $30 Price Target Maintained
18d ago
MLTX
Closing Bell Movers: Avis Budget jumps over 6% on Pentwater settlement
PremiumThe Fly
Closing Bell Movers: Avis Budget jumps over 6% on Pentwater settlement
19d ago
MU
CAR
MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares
PremiumThe Fly
MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares
19d ago
MLTX
MoonLake Reiterated at Buy as Sonelokimab Data Underscore HS Potential; $33 Price Target Maintained
PremiumRatingsMoonLake Reiterated at Buy as Sonelokimab Data Underscore HS Potential; $33 Price Target Maintained
19d ago
MLTX
MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street
Premium
The Fly
MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street
19d ago
MLTX
Buy Rating Reiterated on SLK’s Strong Phase 3 HS Data and BLA Path; $30 Price Target Maintained
Premium
Ratings
Buy Rating Reiterated on SLK’s Strong Phase 3 HS Data and BLA Path; $30 Price Target Maintained
19d ago
MLTX
Midday Fly By: Chevron signs power deal with Microsoft, CRH to acquire Arcosa
PremiumThe Fly
Midday Fly By: Chevron signs power deal with Microsoft, CRH to acquire Arcosa
19d ago
MU
PR
MoonLake Highlights Strong Phase 3 Sonelokimab HS Results
PremiumCompany Announcements
MoonLake Highlights Strong Phase 3 Sonelokimab HS Results
19d ago
8K
MLTX
MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials
PremiumThe Fly
MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials
20d ago
MLTX
MoonLake shareholders back director, auditor and compensation plans
PremiumCompany Announcements
MoonLake shareholders back director, auditor and compensation plans
1M ago
8K
MLTX
MoonLake’s Phase 3 Sonelokimab Trial Reaches Completion in Hidradenitis Suppurativa
PremiumCompany AnnouncementsMoonLake’s Phase 3 Sonelokimab Trial Reaches Completion in Hidradenitis Suppurativa
1M ago
MLTX
Moonlake’s Phase 3 Hidradenitis Trial Hits Completion, Setting Up Key Catalyst for MLTX
Premium
Company Announcements
Moonlake’s Phase 3 Hidradenitis Trial Hits Completion, Setting Up Key Catalyst for MLTX
1M ago
MLTX
MoonLake Secures Long-Term Manufacturing Capacity with Vetter Pharma
Premium
Company Announcements
MoonLake Secures Long-Term Manufacturing Capacity with Vetter Pharma
1M ago
8K
MLTX
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained
PremiumRatings
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained
2M ago
MLTX
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential
PremiumRatings
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential
2M ago
MLTX
MoonLake advances sonelokimab toward BLA after positive FDA meeting
PremiumCompany Announcements
MoonLake advances sonelokimab toward BLA after positive FDA meeting
2M ago
8K
MLTX
MoonLake price target raised to $45 from $40 at H.C. Wainwright
PremiumThe Fly
MoonLake price target raised to $45 from $40 at H.C. Wainwright
2M ago
MLTX
MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street
PremiumThe FlyMoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street
2M ago
MLTX
MoonLake says aligned with FDA on submission plans for sonelokimab
Premium
The Fly
MoonLake says aligned with FDA on submission plans for sonelokimab
2M ago
MLTX
MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year
Premium
The Fly
MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year
2M ago
MLTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >